Canadian stem cell technology expected to offer new options for blood stem cell transplants

Peter Zandstra receives the 2013 Till & McCulloch Award

OTTAWA, Sept. 25, 2013 /CNW/ - A Canadian technology that has the potential to boost the number of stem cells given to patients undergoing transplants of the blood-forming system has been recognized as the most impactful stem cell research paper authored by a Canadian in the past year. Dr. Peter Zandstra has been given the 2013 Till & McCulloch Award in recognition of this contribution to global stem cell research. Dr. Zandstra will accept the award and present a lecture entitled "Engineering pluripotent stem cell derived microtissues" as part of the Till & McCulloch Meetings, Canada's premier stem cell event.

Dr. Michael Rudnicki, Scientific Director of the Stem Cell Network, who launched the Till & McCulloch Award in 2005 and will make the award presentation, says the Zandstra group's publication was chosen due to the impact their technology is expected to have. "This technology will hasten the promise of regenerative medicine and the therapeutic possibilities of umbilical cord blood and hematopoietic stem cells in particular. It is very likely that Fed-Batch technology will improve the outcome of blood system transplants for many patients. We are proud to award the 2013 lecture to Dr. Zandstra for his pioneering work."

First author Elizabeth Csaszar, Zandstra and his team have developed a new culture system that has the ability to dramatically expand the clinical applications of hematopoietic (blood) stem cells (HSCs). Their breakthrough discovery is based on a Fed-Batch bioreactor technology and has the potential to improve the viability and success of cord blood stem cell transplantation by allowing for better-matched donors and increasing the number of stem cells in a transplant unit.

This new system will accelerate the possibilities of using HSC transplantation in clinical settings, especially in the treatment of certain forms of leukemia. The success rate of blood system transplantation is strongly correlated to the number of cells used. Dr. Zandstra's Fed-Batch technology can produce over 11 times more HSCs than originally existed and is designed to be adaptively scaled-up for human transplantations in clinical settings.

The article for which the award was granted, published in the February 2012 issue of Cell Stem Cell, entitled "Rapid Expansion of Human Hematopoietic Stem Cells by Automated Control of Inhibitory Feedback Signaling," explains this novel discovery to expand cord blood cells. Dr. Zandstra is a professor at the University of Toronto'sInstitute for Biomaterials & Biomedical Engineering, a principal investigator with the McEwen Centre for Regenerative Medicine and the Chief Scientific Officer at the Centre for Commercialization of Regenerative Medicine.

Dr. Zandstra, the Canadian Research Chair in Stem Cell Bioengineering, was very pleased to learn he had been chosen for this honour. "When I was told I would be receiving the 2013 lecture award, I was very honoured to be recognized in this way by the scientific community. I am thrilled to be in the same company as the previous winners, who are all exceptional researchers in our field and help to drive advances in health care that will improve the lives of many. This technology, and others being supported and developed through the Stem Cell Network, the Leukemia and Lymphoma Society and CCRM funding, represents an exciting opportunity for Canadian leadership in the clinically important area of cell transplantation to treat leukemia."

View original post here:
Canadian stem cell technology expected to offer new options for blood stem cell transplants